--- title: "ZNTL.US (ZNTL.US) — Related News" type: "Symbol" locale: "en" url: "https://longbridge.com/en/quote/ZNTL.US/news.md" symbol: "ZNTL.US" name: "ZNTL.US" parent: "https://longbridge.com/en/quote/ZNTL.US.md" datetime: "2026-05-20T12:03:22.076Z" locales: - [en](https://longbridge.com/en/quote/ZNTL.US/news.md) - [zh-CN](https://longbridge.com/zh-CN/quote/ZNTL.US/news.md) - [zh-HK](https://longbridge.com/zh-HK/quote/ZNTL.US/news.md) --- # ZNTL.US (ZNTL.US) — Related News ### [Wedbush Keeps Their Hold Rating on Zentalis Pharmaceuticals (ZNTL)](https://longbridge.com/en/news/286285617.md) *2026-05-13T15:16:12.000Z* > Wedbush analyst maintained a Hold rating on Zentalis Pharmaceuticals today and set a price target of $4.00.Claim 55% Off ### [Zentalis: Buy Rating Reiterated as Azenosertib Strategy Advances; $10 Price Target Maintained on De-Risked Dosing and Late-Stage Catalysts](https://longbridge.com/en/news/286240587.md) *2026-05-13T10:20:07.000Z* > Analyst Andres Y. Maldonado from H.C. Wainwright has reiterated a Buy rating on Zentalis Pharmaceuticals, maintaining a ### [ZeZentalis Pharma | 10-Q: FY2026 Q1 Revenue: USD 0](https://longbridge.com/en/news/286151877.md) *2026-05-12T20:21:55.000Z* ### [](https://longbridge.com/en/news/285421024.md) *2026-05-06T18:15:43.000Z* > Bayer has agreed to acquire Perfuse Therapeutics for up to $2.45 billion, with $300 million upfront. Madrigal Pharmaceut ### [](https://longbridge.com/en/news/285395102.md) *2026-05-06T14:04:18.000Z* > Zentalis Pharmaceuticals has initiated the Aspenova Phase III trial, dosing its first patient to evaluate azenosertib, a ### [Zentalis doses first patient in Phase 3 ASPENOVA trial for Cyclin E1-positive PROC](https://longbridge.com/en/news/285202157.md) *2026-05-05T12:03:00.000Z* > Zentalis Pharmaceuticals has initiated the Phase 3 ASPENOVA trial by dosing the first patient. This trial will evaluate